Stream Bio Ltd today presented its revolutionary Conjugated Polymer Nanoparticle (CPN™) technology at the opening of the Centre for Process Innovation’s (CPI) National Formulation Centre.
The official opening of the centre included tours of the new facilities, networking opportunities for both industrialists and academics, and presentations on the centre’s capabilities. Stream was the only SME invited to deliver a presentation at the event, appearing alongside formulation industry leaders including snack food giant, Mondelez, big pharma, AstraZeneca, Pfizer and GSK, and global personal care experts, Proctor & Gamble. Stream’s talk explored the company’s business strategy, the need for CPN™-based, non-toxic molecular bioimaging probes in the biotech market, and how the National Formulation Centre has assisted in commercialising robust and reliable CPN™ technology out of the Kings College London lab.
Based at the NETPark site at Sedgefield, County Durham, the national centre is supporting the development and commercialisation of new innovations in formulation science. Formulation chemistry is the basis of multiple markets, including pharmaceuticals, oils, gas, and lubricants. However, manufacturing these products can be challenging and comes with financial risks.
The new centre’s state-of-the-art facilities, coupled with the expertise of professionals at CPI, greatly improve aspects of these manufacturing processes and thus minimise the risks associated with developing formulation-based products. A dedicated team of over 50 highly trained scientists at the open-access facility work with SMEs, such as Stream, big corporates and academic partners to test new products and processes from bench to pilot scale.
Stream Bio’s CEO, Andy Chaloner, who presented on behalf of Stream at the launch event, said: “The event was a great opportunity to network with leaders in the formulation industry and share the work of Stream to a highly relevant audience. CPI’s expertise and formulation capabilities have been integral to commercialising our CPN™ technology, and providing us with the necessary Proof of Concept work to bridge the gap from academic innovation to commercial reality.”
John Jappy, Patent Attorney at Gill Jennings & Every LLP, who works with Stream Bio and attended the event, said: “The collaboration between Stream Bio and CPI has been very effective, and this event was a great opportunity to demonstrate to industry-leading experts the huge potential in Stream’s CPN™ technology. Andy’s presentation was very well received.”